Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Supplemental digital content 1: Search terms, criteria for study selection and articles identified. PubMed and EMBASE (1947 to present) were searched using the following terms in the format Disease AND Setting: Disease: Text Words [Ovary OR Ovari*] AND [tumo(u)r* OR cancer(s) OR malignanc* OR neoplasm*] MeSH Words: Ovarian Neoplasms (PubMed only), Ovary Tumor (EMBASE only) Setting: Text Words [Limited OR Low(er)] AND [resource OR income] AND [countr* OR setting OR environment] OR “third world” OR [developing AND country(ies)] MeSH Words: Developing Countries. We also included as MeSH Words the names of all lower and lowermiddle income countries as defined by the World Bank1 and all countries in Sub-Saharan Africa. Criteria for study selection: Studies were included if they were conducted in a developing country and mentioned each of the following: Ovarian Epithelial Cancer, Survival or Response Rate, Specific Chemotherapeutics mentioned (dose not required). We included studies in English or French, regardless of publication date. Studies in which surgery was the primary treatment were excluded. Study selection: Two reviewers (LS, LVL) screened titles and abstracts acquired from all sources listed above for relevance and retrieved full-text of all potentially relevant titles. Two reviewers (LS, JN) independently determined the eligibility of retrieved articles and extracted the following information from relevant studies: Author, Year, Journal, Country, Type of Study, Number of patients, Patient Characteristics, FIGO Stage, Chemotherapy/Dose/Cycle length, Response Rate, Survival. Fourteen studies were potentially relevant: 1-14 1. Attarian H. Carboplatin combined with docetaxel as a first-line chemotherapy in epithelial ovarian cancer. Archives of Iranian Medicine 2003;6: 176-9. 2. Basu P, De P, Mandal S et al. Study of 'patterns of care' of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India. Indian J Cancer 2009;46: 28-33. 3. Charak BS, Agarwala S, Gopal R et al. Cisplatin-based chemotherapy in advanced ovarian cancer: initial experience in an Indian set-up. Indian J Cancer 1989;26: 85-91. 4. Dunder I, Berker B, Atabekoglu C, Bilgin T. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. Eur J Gynaecol Oncol 2005;26: 79-82. 5. Ghaemmaghami F, Karimi-Zarchi M, Modares-Gilani M et al. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery. Asian Pac J Cancer Prev 2008;9: 719-24. 6. Karabulut B, Sezgin C, Terek MC et al. Topotecan in platinum-resistant epithelial ovarian cancer. Chemotherapy 2005;51: 347-51. 7. Malik IA. An open label evaluation of topotecan in patients with relapsed or refractory epithelial ovarian cancer - single institution experience in a developing country. Int J Gynecol Cancer 2000;10: 443-8. 8. Moosavi AS, Gilani MM, Tehranian A, Esfahani JK. Daily low-dose oral etoposide for recurrent epithelial ovarian cancer after platinum-based therapy. J Obstet Gynaecol 2004;24: 292-3. 9. Piura B, Meirovitz M. Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma. European Journal of Gynaecological Oncology 2005;26: 386-90. 10. Piura B, Rabinovich A. Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma. European Journal of Gynaecological Oncology 2004;25: 449-52. 11. Senapad S. Chemotherapy for gynecologic malignancies at Siriraj Hospital, Bangkok. Southeast Asian J Trop Med Public Health 1985;16: 656-9. 12. Sonnendecker EW. Cancer of the ovary. The Johannesburg Hospital experience. S Afr Med J 1988;73: 713-5. 13. Sulkes A, Beller U, Peretz T et al. Taxol: initial Israeli experience with a novel anticancer agent. Isr J Med Sci 1994;30: 70-8. 14. Vanderpuye V, Yarney J. Ovarian cancer: an analysis of forty-four patients at the National Radiotherapy Centre, Accra--Ghana. West Afr J Med 2007;26: 93-6. REFERENCES 1. World Bank Country Classification: Country and Lending Groups [database online]. Washington, DC: The World Bank Group. Updated August 2010. Available at: http://data.worldbank.org/about/country-classifications. Accessed January 2010.